Sonnet BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Overview
    • Platform
    • Strategy
    • Progress
    • Publications
  • Pipeline
    • Overview
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Publications

Technology

Technology

  • Overview
  • Platform
  • Strategy
  • Progress
  • Publications

An Innovative Human Platform for Targeted Delivery of Bispecific Interleukins to Tumors

April 2022

Presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting

View Publication

Toxicity Profile of Interleukin 12 Attached to a Fully Human Albumin Binding Domain (FHAB™) in Cynomolgus Macaques

May 2021

Presented at the 2021 American Association of Cancer Research (AACR) Annual Meeting

View Publication

A Novel Strategy to Produce High Level and High Purity of Bioactive IL15 Fusion Proteins from Mammalian Cells

August 2018

Protein Expression and Purification 148 (2018) 30–39

View Publication

In vivo Effect of Albumin Binding Domains (ABD) Attached to Immune Modulators

November 2017

Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting

View Publication

Enhanced Efficacy of Immune Modulators with Albumin Binding Domains (ABD)

October 2017

Presented at American Association of Cancer Research (AACR) Annual Meeting

View Publication

RSS
© 2023 Sonnet BioTherapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap